Company profile
Lyra Therapeutics, Inc.
NASDAQ: LYRA · Healthcare · Biotechnology
#950 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
30DFH 27DQ 40GM 18SS 35
v0.1 · 65/100 weight · provisional
↑ filing timeliness, Piotroski F · ↓ operating margin, net margin
Methodology →Revenue TTM
$398.0k
Rev growth YoY (TTM)
-74.1%
Net income (FY)
-$28.9M
Employees
30
as of 2026-07-19
Market cap
$851.9k
as of 2026-07-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$398.0k$398.0k2025
Net income-$28.9M-$28.9M2025
Operating income-$31.0M-$31.0M2025
Total assets$36.1M$36.1M2025
Liabilities$46.8M$46.8M2025
Equity-$10.7M-$10.7M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Lyra Therapeutics, Inc.’s revenue?
Lyra Therapeutics, Inc. booked $398.0k in FY2025 revenue, contracting 74% year over year — slower than 87% of Healthcare companies we track, at a -7266.1% net margin.
Peers · Healthcare
Cartesian Therapeutics, Inc.40DiBio, Inc.48DNeurogenesis, Inc.——OMID Holdings, Inc.48DAmerica Great Health39DBioRestorative Therapies, Inc.38DNeighbors
Middlesex →Key facts
CEOCarmichael S. Roberts Jr.
SectorHealthcare
IndustryBiotechnology
HeadquartersWatertown, MA
ExchangeNASDAQ: LYRA
Employees30
IPO date2020-05-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.